379 GENES FOUND
Show / hide columns
XML |
RDF |
TSV |
« prev | Page
of 8 | next »
IL2RA Interleukin 2 receptor, alpha Cancer-related genes CD markers Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Tissue enhanced
IL2RB Interleukin 2 receptor, beta Cancer-related genes CD markers FDA approved drug targets Predicted membrane proteins Predicted secreted proteins Tissue enhanced
IL2RG Interleukin 2 receptor, gamma Cancer-related genes CD markers Disease related genes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Vesicles Tissue enhanced
IL3RA Interleukin 3 receptor, alpha (low affinity) CD markers FDA approved drug targets Predicted membrane proteins Predicted secreted proteins Expressed in all
IL6R Interleukin 6 receptor Cancer-related genes Candidate cardiovascular disease genes CD markers FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins Expressed in all
INSR Insulin receptor CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins RAS pathway related proteins Vesicles Expressed in all
ITGA2B Integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41) Cancer-related genes Candidate cardiovascular disease genes CD markers Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Nucleoplasm Cell Junctions Cytosol Tissue enhanced
ITGA4 Integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor) Cancer-related genes CD markers FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins Golgi apparatus Vesicles Tissue enhanced
ITGAL Integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide) CD markers FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins Tissue enhanced
ITGAV Integrin, alpha V Cancer-related genes CD markers FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Focal adhesion sites Cytosol Expressed in all
ITGB1 Integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12) Cancer-related genes CD markers FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins Transporters Endoplasmic reticulum Plasma membrane Focal adhesion sites Expressed in all
ITGB3 Integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) Cancer-related genes CD markers Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins Tissue enhanced
ITGB7 Integrin, beta 7 Cancer-related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins Plasma membrane Cytosol Mixed
KCNA1 Potassium channel, voltage gated shaker related subfamily A, member 1 Disease related genes FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels Tissue enriched
KCNA10 Potassium channel, voltage gated shaker related subfamily A, member 10 FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels Nucleoplasm Cytosol Tissue enhanced
KCNA2 Potassium channel, voltage gated shaker related subfamily A, member 2 Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels Tissue enriched
KCNA3 Potassium channel, voltage gated shaker related subfamily A, member 3 FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels Mixed
KCNA4 Potassium channel, voltage gated shaker related subfamily A, member 4 FDA approved drug targets Plasma proteins Predicted membrane proteins Voltage-gated ion channels Tissue enhanced
KCNA5 Potassium channel, voltage gated shaker related subfamily A, member 5 Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels Tissue enhanced
KCNA6 Potassium voltage-gated channel subfamily A member 6 FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels Not detected
KCNA7 Potassium channel, voltage gated shaker related subfamily A, member 7 FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels Tissue enriched
KCNB1 Potassium channel, voltage gated Shab related subfamily B, member 1 Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels Tissue enhanced
KCNB2 Potassium channel, voltage gated Shab related subfamily B, member 2 FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels Nucleoli Plasma membrane Midbody Tissue enhanced
KCNC1 Potassium channel, voltage gated Shaw related subfamily C, member 1 Disease related genes FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels Nucleus Nuclear membrane Vesicles Cytosol Tissue enriched
KCNC2 Potassium channel, voltage gated Shaw related subfamily C, member 2 FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels Plasma membrane Cytosol Tissue enriched
KCNC3 Potassium channel, voltage gated Shaw related subfamily C, member 3 Disease related genes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Transporters Voltage-gated ion channels Tissue enhanced
KCND1 Potassium channel, voltage gated Shal related subfamily D, member 1 FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Voltage-gated ion channels Nucleus Mixed
KCND2 Potassium channel, voltage gated Shal related subfamily D, member 2 Disease related genes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Transporters Voltage-gated ion channels Tissue enhanced
KCND3 Potassium channel, voltage gated Shal related subfamily D, member 3 Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels Mixed
KCNE1 Potassium channel, voltage gated subfamily E regulatory beta subunit 1 Disease related genes FDA approved drug targets Predicted membrane proteins Tissue enhanced
KCNH2 Potassium channel, voltage gated eag related subfamily H, member 2 Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels Tissue enhanced
KCNJ1 Potassium channel, inwardly rectifying subfamily J, member 1 Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels Tissue enriched
KCNJ11 Potassium channel, inwardly rectifying subfamily J, member 11 Disease related genes FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels Tissue enhanced
KCNJ12 Potassium channel, inwardly rectifying subfamily J, member 12 FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels Nucleoplasm Golgi apparatus Cytosol Group enriched
KCNJ8 Potassium channel, inwardly rectifying subfamily J, member 8 Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels Mixed
KCNK2 Potassium channel, two pore domain subfamily K, member 2 FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels Mitochondria Cytosol Tissue enhanced
KCNK3 Potassium channel, two pore domain subfamily K, member 3 Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels Tissue enhanced
KCNK9 Potassium channel, two pore domain subfamily K, member 9 Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels Group enriched
KCNMA1 Potassium channel, calcium activated large conductance subfamily M alpha, member 1 Disease related genes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Voltage-gated ion channels Tissue enhanced
KCNN4 Potassium channel, calcium activated intermediate/small conductance subfamily N alpha, member 4 Disease related genes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins Transporters Voltage-gated ion channels Tissue enhanced
KCNQ1 Potassium channel, voltage gated KQT-like subfamily Q, member 1 Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels Tissue enhanced
KCNQ2 Potassium channel, voltage gated KQT-like subfamily Q, member 2 Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Transporters Voltage-gated ion channels Endoplasmic reticulum Tissue enriched
KCNQ3 Potassium channel, voltage gated KQT-like subfamily Q, member 3 Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels Tissue enriched
KDR Kinase insert domain receptor Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins RAS pathway related proteins Plasma membrane Tissue enhanced
KIT V-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins RAS pathway related proteins Plasma membrane Tissue enhanced
LEPR Leptin receptor Cancer-related genes Candidate cardiovascular disease genes CD markers Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Vesicles Mixed
LHCGR Luteinizing hormone/choriogonadotropin receptor Disease related genes FDA approved drug targets G-protein coupled receptors Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins Group enriched
M6PR Mannose-6-phosphate receptor (cation dependent) FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins Expressed in all
MAOA Monoamine oxidase A Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins Mitochondria Mixed
MAOB Monoamine oxidase B Enzymes FDA approved drug targets Predicted membrane proteins Nucleoli Mitochondria Mixed
« prev | Page
of 8 | next »